| 1 |
29922424 |
10.22038/IJBMS.2018.26778.6557 |
2022 |
Development of specific nanobodies (VHH) for CD19 immuno-targeting of human B-lymphocytes. |
CD22 |
| 2 |
33461955 |
10.1016/j.clml.2020.12.008 |
2022 |
Efficacy and Safety of Inotuzumab Ozogamicin (CMC-544) for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis. |
CD22 |
| 3 |
33602684 |
10.1158/1078-0432.CCR-20-2399 |
2022 |
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. |
CD22 |
| 4 |
33627493 |
10.1158/1078-0432.CCR-20-3863 |
2022 |
CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia. |
CD22 |
| 5 |
33640284 |
10.1016/j.clml.2021.01.014 |
2022 |
Successful Treatment of TCF3-HLF-positive Childhood B-ALL with Chimeric Antigen Receptor T-Cell Therapy. |
CD22 |
| 6 |
33722856 |
10.1158/1535-7163.MCT-20-0035 |
2022 |
Calicheamicin Antibody-Drug Conjugates with Improved Properties. |
CD22 |
| 7 |
33740268 |
10.1002/cncr.33469 |
2022 |
Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. |
CD22 |
| 8 |
33839735 |
10.1038/s41408-021-00465-9 |
2022 |
A novel full-human CD22-CAR T cell therapy with potent activity against CD22<sup>low</sup> B-ALL. |
CD22 |
| 9 |
33887152 |
10.1089/cbr.2020.4653 |
2022 |
<sup>227</sup>Th-Labeled Anti-CD22 Antibody (BAY 1862864) in Relapsed/Refractory CD22-Positive Non-Hodgkin Lymphoma: A First-in-Human, Phase I Study. |
CD22 |
| 10 |
34088894 |
10.1038/s41408-021-00499-z |
2022 |
Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins. |
CD22 |
| 11 |
34097135 |
10.1007/s11864-021-00859-8 |
2022 |
Current Status of CAR T Cell Therapy for Leukemias. |
CD22 |
| 12 |
34160005 |
10.1093/ajcp/aqab057 |
2022 |
LILRB1: A Novel Diagnostic B-Cell Marker to Distinguish Neoplastic B Lymphoblasts From Hematogones. |
CD22 |
| 13 |
34239307 |
10.2147/OTT.S312904 |
2022 |
Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy. |
CD22 |
| 14 |
34290048 |
10.1158/2326-6066.CIR-20-0675 |
2022 |
CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study. |
CD22 |
| 15 |
34407735 |
10.1080/10428194.2021.1966780 |
2022 |
A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas. |
CD22 |
| 16 |
34425260 |
10.1016/j.jtct.2021.08.012 |
2022 |
CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas. |
CD22 |
| 17 |
34521107 |
10.1182/bloodadvances.2021004557 |
2022 |
Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma. |
CD22 |
| 18 |
34590432 |
10.1111/1759-7714.14155 |
2022 |
Primary mediastinal large B cell lymphoma. |
CD22 |
| 19 |
34625226 |
10.1016/j.beha.2021.101277 |
2022 |
New targets for CAR T therapy in hematologic malignancies. |
CD22 |
| 20 |
34625231 |
10.1016/j.beha.2021.101305 |
2022 |
Clinical experience of CAR T cells for B cell acute lymphoblastic leukemia. |
CD22 |
| 21 |
34667217 |
10.1038/s41598-021-00227-4 |
2022 |
Upregulation of CD22 by Chidamide promotes CAR T cells functionality. |
CD22 |
| 22 |
34686527 |
10.1158/2159-8290.CD-RW2021-150 |
2022 |
Dual CD19/CD22 CAR T Cells Show Feasibility in Pediatric/Young Adult B-ALL. |
CD22 |
| 23 |
34691067 |
10.3389/fimmu.2021.751754 |
2022 |
Case Report: Post-CAR-T Infusion HBV Reactivation in Two Lymphoma Patients Despite Entecavir Preventive Therapy. |
CD22 |
| 24 |
34710243 |
10.1002/ajh.26390 |
2022 |
Hairy cell leukemia 2022: Update on diagnosis, risk-stratification, and treatment. |
CD22 |
| 25 |
34840026 |
10.1016/j.ejca.2021.10.016 |
2022 |
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. |
CD22 |
| 26 |
34882493 |
10.1200/JCO.20.03585 |
2022 |
Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report. |
CD22 |
| 27 |
34920453 |
10.1182/bloodadvances.2021006035 |
2022 |
Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy. |
CD22 |
| 28 |
34922844 |
10.1016/j.clml.2021.11.010 |
2022 |
The Novel Therapeutic Landscape for Relapsed/Refractory Diffuse Large B Cell Lymphoma. |
CD22 |
| 29 |
34973016 |
10.1007/978-3-030-78775-2_14 |
2022 |
Adiponectin and Its Effects on Acute Leukemia Cells: An Experimental and Bioinformatics Approach. |
CD22 |
| 30 |
35007127 |
10.1200/JCO.21.01693 |
2022 |
Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621. |
CD22 |
| 31 |
35013921 |
10.1007/s12029-021-00790-z |
2022 |
Spindle Variant Primary Diffuse Large B Cell Lymphoma of the Colon: Case Report and Literature Review. |
CD22 |
| 32 |
35015683 |
10.1158/2643-3230.BCD-21-0087 |
2022 |
Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed Immunotherapies. |
CD22 |
| 33 |
35015686 |
10.1158/2643-3230.BCD-21-0200 |
2022 |
Splicing-Mediated Antigen Escape from Immunotherapy for B-cell Malignancies. |
CD22 |
| 34 |
35042232 |
10.1182/bloodadvances.2021005978 |
2022 |
Outcomes of relapsed B-cell acute lymphoblastic leukemia after sequential treatment with blinatumomab and inotuzumab. |
CD22 |
| 35 |
35051588 |
10.1016/j.trim.2022.101538 |
2022 |
Nanobody-based anti-CD22-chimeric antigen receptor T cell immunotherapy exhibits improved remission against B-cell acute lymphoblastic leukemia. |
CD22 |
| 36 |
35092855 |
10.1016/j.nano.2022.102523 |
2022 |
Overcoming the blood-brain barrier by using a multistage exosome delivery system to inhibit central nervous system lymphoma. |
CD22 |
| 37 |
35121370 |
10.1016/j.ejca.2021.12.029 |
2022 |
Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma. |
CD22 |
| 38 |
35198451 |
10.3389/fonc.2022.834288 |
2022 |
Prognostic Value of Radiomic Features of <sup>18</sup>F-FDG PET/CT in Patients With B-Cell Lymphoma Treated With CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T Cells. |
CD22 |
| 39 |
35222407 |
10.3389/fimmu.2022.825364 |
2022 |
Bryostatin Activates CAR T-Cell Antigen-Non-Specific Killing (CTAK), and CAR-T NK-Like Killing for Pre-B ALL, While Blocking Cytolysis of a Burkitt Lymphoma Cell Line. |
CD22 |
| 40 |
35253074 |
10.1186/s43046-022-00107-6 |
2022 |
Simple headache revealed a rare lymphoma: Waldenstrom macroglobulinemia with unique markers: a case report and review of the literature. |
CD22 |
| 41 |
35288466 |
10.1136/jitc-2021-003882 |
2022 |
A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL. |
CD22 |
| 42 |
35293685 |
10.1002/pbc.29664 |
2022 |
Direct CNS administration of rituximab and epratuzumab in a pediatric patient with relapsed refractory CNS B-cell acute lymphoblastic leukemia. |
CD22 |
| 43 |
35399106 |
10.1038/s41392-022-00924-0 |
2022 |
Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT. |
CD22 |
| 44 |
35405786 |
10.3760/cma.j.issn.0253-2727.2022.03.013 |
2022 |
[Sequential infusion of anti-CD22 and anti-CD19 CAR-T cells in the treatment of relapsed / refractory childhood acute B lymphoblastic leukemia: two cases report]. |
CD22 |
| 45 |
35419923 |
10.1111/ijlh.13850 |
2022 |
Haematology laboratory parameters to assess efficacy of CD19-, CD22-, CD33-, and CD123-directed chimeric antigen receptor T-cell therapy in haematological malignancies. |
CD22 |
| 46 |
35421218 |
10.1182/blood.2021014840 |
2022 |
CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies. |
CD22 |
| 47 |
35422632 |
10.2147/OTT.S352760 |
2022 |
CAR T-Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Progressive Muscular Dystrophy: A Case Report. |
CD22 |
| 48 |
35442136 |
10.1080/10428194.2022.2062346 |
2022 |
CD22 expression in acute myeloid leukemia: close correlation with interleukin-2 receptor α-chain (CD25) expression and poor prognosis. |
CD22 |
| 49 |
35450208 |
10.1177/20406207221090886 |
2022 |
Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib. |
CD22 |
| 50 |
35468945 |
10.1038/s41375-022-01576-3 |
2022 |
Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial. |
CD22 |
| 51 |
35486592 |
10.1080/08830185.2022.2067154 |
2022 |
Scaling up and scaling out: Advances and challenges in manufacturing engineered T cell therapies. |
CD22 |
| 52 |
35534047 |
10.1136/jitc-2021-004483 |
2022 |
Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation. |
CD22 |
| 53 |
35572515 |
10.3389/fimmu.2022.873789 |
2022 |
T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma. |
CD22 |
| 54 |
35574341 |
10.3389/fonc.2022.817969 |
2022 |
Sequential CAR T-Cell Therapy After Autologous Stem Cell Transplantation for the Treatment of Relapsed/Refractory Intravascular Large B-Cell Lymphoma With Central Nervous System Involvement: A Case Report. |
CD22 |
| 55 |
35605184 |
10.1182/blood.2022015795 |
2022 |
CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR. |
CD22 |
| 56 |
35622074 |
10.1080/16078454.2022.2074704 |
2022 |
Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia. |
CD22 |
| 57 |
35643855 |
10.1016/j.clml.2022.04.022 |
2022 |
Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial. |
CD22 |
| 58 |
35653589 |
10.1080/14712598.2022.2086043 |
2022 |
Bispecific CAR T-cells for B-cell Malignancies. |
CD22 |
| 59 |
35663281 |
10.1016/j.lrr.2022.100325 |
2022 |
Immunotherapy in indolent Non-Hodgkin's Lymphoma. |
CD22 |
| 60 |
35669773 |
10.3389/fimmu.2022.879983 |
2022 |
Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma. |
CD22 |
| 61 |
35673721 |
10.3760/cma.j.cn112151-20211117-00836 |
2022 |
[ALK-positive large B-cell lymphoma with EBV infection or cyclin D1 expression: a clinicopathological analysis of 3 cases]. |
CD22 |
| 62 |
35727422 |
10.1007/s10815-022-02548-3 |
2022 |
Primary ovarian insufficiency secondary to chemotherapy with inotuzumab ozogamicin and other agents. |
CD22 |
| 63 |
35779772 |
10.1016/j.actbio.2022.06.033 |
2022 |
Polysialylated nanoinducer for precisely enhancing apoptosis and anti-tumor immune response in B-cell lymphoma. |
CD22 |
| 64 |
35787551 |
10.1097/MOH.0000000000000723 |
2022 |
Clinical trials for chimeric antigen receptor T-cell therapy: lessons learned and future directions. |
CD22 |
| 65 |
35979928 |
10.1177/09636897221117532 |
2022 |
A Case of Central Nervous System Post-Transplant Lymphoproliferative Disorder Following Haploidentical Stem Cell Transplantation in a Patient With Acute Lymphoblastic Leukemia. |
CD22 |
| 66 |
36059496 |
10.3389/fimmu.2022.965224 |
2022 |
Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma. |
CD22 |
| 67 |
36059523 |
10.3389/fimmu.2022.969660 |
2022 |
Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients. |
CD22 |
| 68 |
36093513 |
10.21037/tcr-22-174 |
2022 |
Allogeneic CAR-T bridging to allo-HSCT as a treatment strategy for refractory adult Burkitt's lymphoma: a case report. |
CD22 |
| 69 |
23264893 |
10.4161/onci.21815 |
2021 |
Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin's lymphoma. |
CD22 |
| 70 |
31585889 |
10.2741/4806 |
2021 |
Transferrin epitope-CD19-CAR-T cells effectively kill lymphoma cells <i>in vitro</i> and <i>in vivo</i>. |
CD22 |
| 71 |
31900459 |
10.1038/s41423-019-0355-5 |
2021 |
Efficiency and side effects of anti-CD38 CAR T cells in an adult patient with relapsed B-ALL after failure of bi-specific CD19/CD22 CAR T cell treatment. |
CD22 |
| 72 |
32005917 |
10.1038/s41409-020-0807-7 |
2021 |
CD19/CD22 chimeric antigen receptor T-cell therapy for refractory acute B-cell lymphoblastic leukemia with FLT3-ITD mutations. |
CD22 |
| 73 |
32032771 |
10.1016/j.pep.2020.105594 |
2021 |
Bacterial expression and characterization of an anti-CD22 single-chain antibody fragment. |
CD22 |
| 74 |
32245502 |
10.1186/s13045-020-00856-8 |
2021 |
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. |
CD22 |
| 75 |
32281503 |
10.1080/10428194.2020.1742902 |
2021 |
Immunophenotypic modulation in pediatric B lymphoblastic leukemia and its implications in MRD detection. |
CD22 |
| 76 |
32286905 |
10.1200/JCO.19.03279 |
2021 |
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial. |
CD22 |
| 77 |
32291234 |
10.1016/j.clml.2020.03.004 |
2021 |
Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin. |
CD22 |
| 78 |
32345625 |
10.1136/jitc-2019-000364 |
2021 |
CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome. |
CD22 |
| 79 |
32424837 |
10.1111/bjh.16732 |
2021 |
Inotuzumab ozogamicin compassionate use for French paediatric patients with relapsed or refractory CD22-positive B-cell acute lymphoblastic leukaemia. |
CD22 |
| 80 |
32436925 |
10.1039/d0nr02133d |
2021 |
Identification of a moderate affinity CD22 binding peptide and in vitro optimization of peptide-targeted nanoparticles for selective uptake by CD22+ B-cell malignancies. |
CD22 |
| 81 |
32459397 |
10.1111/jcmm.15425 |
2021 |
Establishment and characterization of a novel 'double-hit' follicular lymphoma cell line, FL-SJC. |
CD22 |
| 82 |
32495161 |
10.1007/s11523-020-00729-7 |
2021 |
Targeting CD79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas. |
CD22 |
| 83 |
32497402 |
10.1002/cyto.b.21887 |
2021 |
Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double-hit high-grade B-cell lymphoma, and single-hit MYC-rearranged diffuse large B-cell lymphoma. |
CD22 |
| 84 |
32503572 |
10.1186/s13045-020-00905-2 |
2021 |
Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. |
CD22 |
| 85 |
32589304 |
10.1634/theoncologist.2020-0560 |
2021 |
CD19/CD22 Dual-Targeted CAR-T Therapy Active in Relapsed/Refractory DLBCL. |
CD22 |
| 86 |
32592176 |
10.1002/eji.202048636 |
2021 |
Humanized CD22 transgenic mouse model for in vivo analysis of anti-CD22-based immunotherapy. |
CD22 |
| 87 |
32648276 |
10.1111/bjh.16949 |
2021 |
Inotuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of B-acute lymphoblastic leukaemia. |
CD22 |
| 88 |
32694050 |
10.1016/j.clml.2020.06.011 |
2021 |
Debate: Transplant Is Still Necessary in the Era of Targeted Cellular Therapy for Acute Lymphoblastic Leukemia. |
CD22 |
| 89 |
32788237 |
10.1136/jitc-2020-000896 |
2021 |
Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope. |
CD22 |
| 90 |
32812370 |
10.1111/cts.12841 |
2021 |
Characterization of the Relationship of Inotuzumab Ozogamicin Exposure With Efficacy and Safety End Points in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. |
CD22 |
| 91 |
32951102 |
10.1007/s12185-020-03006-5 |
2021 |
Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion. |
CD22 |
| 92 |
32988266 |
10.1080/10428194.2020.1827247 |
2021 |
Hepatic veno-occlusive disease in allogeneic stem cell transplant recipients with prior exposure to gemtuzumab ozogamicin or inotuzumab ozogamicin. |
CD22 |
| 93 |
33067614 |
10.1182/blood.2020007848 |
2021 |
A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study). |
CD22 |
| 94 |
33077713 |
10.1038/s41408-020-00371-6 |
2021 |
A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia. |
CD22 |
| 95 |
33098744 |
10.1002/pbc.28718 |
2021 |
Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia. |
CD22 |
| 96 |
33231879 |
10.1002/cncr.33321 |
2021 |
Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia. |
CD22 |
| 97 |
33256899 |
10.1053/j.seminhematol.2020.08.001 |
2021 |
Optimal approach to the treatment of young adults with acute lymphoblastic leukemia in 2020. |
CD22 |
| 98 |
33259039 |
10.1007/s11684-020-0808-3 |
2021 |
A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma. |
CD22 |
| 99 |
33273056 |
10.1158/1535-7163.MCT-20-0046 |
2021 |
An Anti-CD22-<i>seco</i>-CBI-Dimer Antibody-Drug Conjugate (ADC) for the Treatment of Non-Hodgkin Lymphoma That Provides a Longer Duration of Response than Auristatin-Based ADCs in Preclinical Models. |
CD22 |
| 100 |
33279178 |
10.1016/j.beha.2020.101226 |
2021 |
Monoclonal antibodies in frontline acute lymphoblastic leukemia. |
CD22 |
Datasets
Models
